Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Mar 25, 2025; 14(1): 98359
Published online Mar 25, 2025. doi: 10.5501/wjv.v14.i1.98359
Revisiting dexamethasone dosage in COVID-19 management
Abhishet Varama
Abhishet Varama, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Krung Thep Maha Nakhon, Thailand
Author contributions: Abhishet V drafted, wrote and edited the editorial. No external help was used in the making of this manuscript.
Conflict-of-interest statement: The author declares no conflict of interest associated with this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abhishet Varama, BSc, Master's Student, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathum Wan, Bangkok 10330, Krung Thep Maha Nakhon, Thailand. abhishet.varama@docchula.com
Received: June 25, 2024
Revised: November 18, 2024
Accepted: November 26, 2024
Published online: March 25, 2025
Processing time: 155 Days and 22 Hours
Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic has necessitated rapid advancements in therapeutic strategies, with dexamethasone emerging as a key treatment for severe cases. This editorial discusses the systematic review conducted by Sethi et al, published in the World Journal of Virology. The review critically examines the efficacy and safety of varying dosages of dexamethasone in severe COVID-19 patients, providing a comprehensive meta-analysis that underscores the current clinical recommendations favoring a low-dose regimen. Despite these findings, the review highlights the potential benefits of tailored dosages for specific patient subgroups, suggesting a need for personalized treatment approaches. This editorial expands on the implications of these findings, advocating for the integration of evolving clinical data into treatment protocols and calling for further research into patient-specific responses to therapy. It emphasizes the importance of adaptability and precision in pandemic response, urging the medical community to consider both the robustness of existing evidence and the potential for innovative approaches to enhance patient outcomes in the face of global health challenges.

Keywords: COVID-19 treatment; Dexamethasone dosage; Personalized medicine; Editorial; Clinical adaptability

Core Tip: This editorial delves into the critical analysis provided by Sethi et al on dexamethasone dosing in severe coronavirus disease 2019 (COVID-19) cases. Highlighting the review's challenge to the one-size-fits-all approach, it emphasizes the need for personalized medicine and calls for further research to refine treatment protocols based on emerging evidence and patient-specific factors. The editorial advocates for the integration of nuanced clinical data to enhance therapeutic strategies against COVID-19, fostering a broader discussion on the adaptability of clinical practice in pandemic responses and the potential for tailored patient care.